Nano-X Imaging Ltd. Receives EU MDR CE Mark for HealthOST AI Software, Enabling Commercialization Across Europe

Reuters
05 Jun
<a href="https://laohu8.com/S/NNOX">Nano-X Imaging Ltd.</a> Receives EU MDR CE Mark for HealthOST AI Software, Enabling Commercialization Across Europe

Nano-X Imaging Ltd., an innovative medical imaging technology company, announced that its subsidiary, Nanox AI Ltd, has received EU MDR CE mark certification for HealthOST, a software as a medical device for bone health analysis. This certification allows for the commercialization of HealthOST across Europe, ensuring compliance with the highest regulatory standards for medical software. HealthOST provides automated quantification of vertebral parameters from routine CT scans, supporting early identification and preventive care for patients at high fracture risk due to conditions like osteoporosis. This approval marks a significant expansion of Nanox's AI capabilities in Europe, offering healthcare providers a tool to enhance patient outcomes and optimize resource use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nano-X Imaging Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463507-en) on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10